



(11) **EP 1 002 861 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
24.05.2000 Bulletin 2000/21

(51) Int. Cl.⁷: **C12N 15/11**, **C07K 19/00**,
C07K 16/46, **C12N 1/19**,
C12N 15/81

(21) Application number: **99303118.6**

(22) Date of filing: **22.04.1999**

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(74) Representative:
Evans, Jacqueline Gail Victoria et al
Unilever plc
Patent Division
Colworth House
Sharnbrook
Bedford MK44 1LQ (GB)

(30) Priority: **26.10.1998 WO PCT/EP98/06991**

(71) Applicant: **UNILEVER PLC**
London EC4P 4BQ (GB)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(72) Inventor:
The designation of the inventor has not yet been filed

(54) **Antigen-binding proteins comprising a linker which confers restricted conformational flexibility**

(57) Use of a polypeptide linker group, the amino acid sequence of which group confers restricted conformational flexibility, as a linking group to link binding units, preferably antigen binding units comprising heavy chain variable domains derived from an immunoglobulin naturally devoid of light chains, in a multivalent binding protein.

EP 1 002 861 A1

Description

FIELD OF THE INVENTION

5 [0001] The present invention relates to the preparation of multivalent and multispecific binding proteins. In particular, the invention relates to the preparation of antigen binding proteins comprising a plurality of binding units linked in series by means of intervening polypeptide linker groups, the amino acid sequence of which linker groups confer restricted conformational flexibility.

10 BACKGROUND OF THE INVENTION

[0002] There is considerable interest in the preparation of multivalent and/or multispecific antigen binding proteins. Antigen binding proteins which are multivalent (that is, comprise more than one antigen binding site), more especially those which are also multispecific (where the antigen binding sites have differing antigen specificities) have found particular application in the fields of diagnosis or therapy, for example, where the construction of binding proteins having binding activity against both target site and diagnostic or therapeutic agent allows for targeted delivery of the diagnostic or therapeutic agent to the intended site of action. Other uses for which multivalent and multispecific binding proteins have been proposed include assays, such as immunoassays and agglutination assays, and purification processes.

15 [0003] Those multivalent, multispecific antigen binding proteins which have been described in the literature to date rely, in general, on the association of antibody light and heavy chain variable domains for the formation of the antigen binding site.

[0004] Thus, constructs comprising two or more polypeptide chains are described in WO 94/09131 (Scotgen Limited) and WO 97/14719 (Unilever) and WO 97/38102 (Unilever); multivalent molecules comprising two or more single chain Fv molecules linked together are described in WO 93/11161 (Enzon Inc.) and WO 94/13806 (Dow Chemical Co.).

25 [0005] WO 94/04678 (Casterman et al) describes immunoglobulins capable of exhibiting the functional properties of classical, four chain, immunoglobulins but which comprise two heavy polypeptide chains only and are naturally devoid of light polypeptide chains. Fragments corresponding to isolated V_H domains or to V_H dimers linked by the hinge disulphide are also disclosed. These immunoglobulins, which may be isolated from Camelids, do not rely on the association of heavy and light chain variable domains for the formation of the antigen-binding site; instead, the heavy chain variable domain (hereinafter V_{HH}) alone forms the complete antigen binding site, constituting a single domain binding site.

[0006] In their later patent application, WO 96/34103, Casterman et al disclose multivalent, multispecific constructs comprising V_{HH} fragments combined with a linker sequence. Suitable linker sequences disclosed and exemplified are derived from sequences corresponding to the hinge domain of an immunoglobulin devoid of light chains.

35 [0007] In the Applicant's co-pending patent application number PCT/EP98/06991, filed 26th October 1998, there are disclosed multivalent, multispecific antigen-binding proteins comprising a polypeptide comprising in series two or more single domain binding units which are preferably variable domains of a heavy chain derived from an immunoglobulin naturally devoid of light chains. The individual single domain binding units may suitably be linked by means of peptide linkers, preferably flexible peptide linkers, which allow the variable domains to flex in relation to each other with the aim of ensuring that they can bind to multiple antigenic determinants simultaneously.

40 [0008] There remains a continuing need for the development of improved methods for producing multivalent and/or multispecific binding proteins, especially antigen binding proteins. In particular, there is commercial interest in producing molecules which not only have improved binding activity but which also can be produced economically on a large scale.

45 SUMMARY OF THE INVENTION

[0009] In a first aspect, the invention provides the use of a polypeptide group, the amino acid sequence of which group confers restricted conformational flexibility, as a linking group to link binding units in a multivalent binding protein.

50 [0010] The invention also provides a multivalent binding protein comprising a plurality of binding units linked by means of intervening polypeptide linker groups, the amino acid sequence of which linker group confers restricted conformational flexibility.

[0011] The invention further provides a nucleotide sequence encoding a multivalent antigen binding protein according to the invention and cloning and expression vectors comprising such nucleotide sequences. Also provided are host cells transformed with vectors comprising such nucleotide sequences.

55 [0012] As used herein, a 'multivalent binding protein' is a protein which has more than one binding units which allow for specific binding with a molecule partner in a binding pair. Included within this are bivalent, trivalent and so on. Examples of suitable binding units include antigen binding domains of antibodies, binding domains of receptors such as hor-

more receptors, lectins, enzymes, and cell adhesion molecules. A 'multivalent antigen binding protein' is a protein which has more than one antigen binding unit.

[0013] An 'antigen binding unit' is any structure which exhibits antigen-binding activity. This may be an antibody or an immunologically active fragment thereof. An 'antibody' refers to an immunoglobulin which may be derived from natural sources or synthetically produced. Unless indicated otherwise, 'antibody' and 'immunoglobulin' are used synonymously throughout this specification.

[0014] An antibody fragment is a portion of a whole antibody which retains the ability to exhibit antigen-binding activity. The antigen binding site may be formed through association of antibody light and heavy chain variable domains or may comprise individual antibody variable domains, constituting a single domain binding site.

[0015] Suitable fragments include Fab (comprising an antibody light chain associated with the V_H and C_{H1} domains of an antibody heavy chain), Fv (comprising the variable domains of antibody heavy and light chains associated with each other) and scFv (comprising an antibody V_H domain linked to a V_L domain by a flexible peptide linker) fragments. Where the antigen binding site comprises a single variable domain, this may be a heavy chain variable domain, most suitably a heavy chain variable domain derived from an immunoglobulin naturally devoid of light chains.

[0016] 'Restricted conformational flexibility' relates to restriction of movement of the antigen binding units about the backbone of the intervening polypeptide linker group.

[0017] The present invention may be more fully understood with reference to the following description, when read together with the accompanying drawings. For convenience, an antigen binding protein comprising two single binding units is hereinafter referred to as a 'bi-head'.

BRIEF DESCRIPTION OF THE DRAWINGS

[0018]

Figure 1 shows a nucleotide sequence of the PstI-BstEII insert of plasmid pUR4640, encoding the heavy chain variable domain of an anti-RR6 antibody (denoted R9) from a llama.

Figure 2 shows the nucleotide sequence of the PstI-BstEII insert of plasmid pUR4601, encoding the heavy chain variable domain of an anti-hCG antibody (denoted H14) from a llama.

Figure 3 shows a map of plasmid pUR4619.

Figure 4 shows the nucleotide sequence within plasmid pUR4619 which encodes an anti-hCG-anti-RR6 bispecific biheaded antigen-binding protein (denoted H14-R9), missing the first 4 and last 3 amino acids.

Figure 5 shows the A405 signals of an ELISA to determine bispecificity of various H14-R9 biheads.

Figure 6 shows the scores achieved in a rapid assay technology (RAT) format assay following the detection of 1 IU/ml hCG (human chorionic gonadotrophin protein) with various anti-hCG-anti-RR6 bihead antigen binding proteins derived from a llama wherein the anti-hCG and anti-RR6 fragments are linked as follows (see Example 1.5):

Number	Linker	
1	no linker (directly attached)	
2	G-T-S-G-S	(SEQ. ID NO. 1)
3	S-S-S-A-S-A-S-S-A	(SEQ. ID NO. 2)
4	G-S-P-G-S-P-G	(SEQ. ID NO. 3)
5	A-T-T-T-G-S-S-P-G-P-T	(SEQ. ID NO. 4)
6	A-N-H-S-G-N-A-S	(SEQ. ID NO. 5)

Figure 7 shows a comparison of the sensitivity of detection of hCG in a RAT assay using various biheads (see Example 1.5).

DETAILED DESCRIPTION OF THE INVENTION

[0019] The invention is based on the unexpected finding that by using a polypeptide linking group conferring restricted conformational flexibility to link together antigen binding units, multivalent antigen binding proteins having advantageous binding affinity, as demonstrated by their increased sensitivity of diagnosis and detection, are obtained. Furthermore, constructs according to the invention may conveniently be produced at high yields economically and efficiently on a scale appropriate for industrial use.

[0020] As is apparent from the discussion of the background to the invention above, to the extent that multivalent antigen binding constructs comprising separate binding units linked together have been described at all in the literature, the linking means has been provided by flexible peptide groups. Flexibility of conformation in the linker group has been considered desirable in order to allow the multivalent construct to assume the correct orientation to allow simultaneous binding of multiple antigens.

[0021] Surprisingly, the present inventors have found that by restricting the conformational flexibility of the linking polypeptide group, multivalent antigen binding constructs having improved binding affinity may be obtained. This is entirely contrary to the teaching in the art that the linking group should desirably be flexible.

[0022] The invention is applicable to the preparation of multivalent antigen binding constructs comprising antigen binding units where the antigen binding site is formed through association of antibody light and heavy chain variable domains. Preferably, however, the constructs prepared according to the invention comprise a plurality of single domain binding units, more particularly a plurality of heavy chain variable domains derived from an immunoglobulin naturally devoid of light chains such as may be obtained from lymphoid cells, especially peripheral blood lymphocytes, bone marrow cells or spleen cells derived from Camelids as described in WO 94/04678 (Casterman et al) discussed above. An advantage of using single domain binding units which are heavy chain variable domains derived from Camelids is that they can readily and conveniently be produced economically on a large scale, for example, using a transformed lower eukaryotic host, as described in WO 94/25591 (Unilever), described above.

[0023] Bivalent forms, that is having two antigen binding sites, of the multivalent antigen binding proteins prepared according to the invention are preferred but it will be appreciated that higher multivalent forms, which are also encompassed in the present invention, may find application under suitable circumstances, for example where more than two antigens are required to bind, for example in processes for scavenging molecules from solution or processes where close proximity of molecules form the basis of an assay.

[0024] Structural features which may suitably be incorporated into the linking polypeptide group in order to achieve the effect of restricting conformational flexibility according to the purposes of the invention would readily suggest themselves to those skilled in the art.

[0025] Accordingly, in one embodiment, the linker group preferably comprises one or more proline residues.

[0026] Without wishing to be bound by theory, it is generally thought that the presence of a proline residue in a peptide sequence encourages the amino acid backbone of the peptide to adopt a beta-turn structural configuration, with the peptide backbone changing direction about the proline residue. Linker groups comprising other sequence features which promote the formation of a beta-turn configuration in the peptide backbone, such as peptide linkers containing valine residues or constrained residues such as 8-bicyclic and 5,9-bicyclic tripeptide units (see, for example, Johansson et al, J. Med. Chem., 42, 601-608 (1999), may also suitably find application in the present invention.

[0027] In another embodiment, peptide linker groups derived from naturally occurring proteins such as cell wall proteins (CWP), in particular, CWP1, or cellobiohydrolases (CBH), such as CBH1P, which serve to restrict conformational flexibility or linker groups showing at least 50% homology thereto as determined by the ALIGN program of Dayhoff et al (1983), Methods Enzymol., 91, 524-545, may also suitably be used according to the invention.

[0028] Peptide linker groups which encode a glycosylation binding site and/or are resistant to proteolytic attack may also suitably be employed. Here, the presence of a carbohydrate attached to the amino acid residues has the effect of restricting the flexibility of the peptide backbone.

[0029] Conveniently, the polypeptide linking group according to the invention comprises from 4 to 30 amino acid residues, preferably from 5 to 15 amino acid residues.

[0030] Preferred polypeptide linking groups according to the invention comprise an amino acid sequence selected from:

S-S-S-A-S-A-S-S-A, (SEQ. ID NO. 2)

G-S-P-G-S-P-G, (SEQ. ID NO. 3)

A-T-T-T-G-S-S-P-G-P-T (SEQ. ID NO. 4)

[0031] It will be appreciated that although the invention has been described primarily by reference to antigen binding proteins, it is equally applicable to proteins comprising other binding units as described above. References to antigen binding proteins will accordingly be understood to refer also to such other proteins unless the context dictates

otherwise.

[0032] Multivalent antigen binding proteins according to the invention may be prepared by transforming a host by incorporating a gene encoding the polypeptide as set forth above and expressing said gene in said host.

[0033] Suitably the host or hosts may be selected from prokaryotic bacteria, such as Gram-negative bacteria, for example *E. coli*, and Gram-positive bacteria, for example *B. subtilis* or lactic acid bacteria, lower eukaryotes such as yeasts, for example belonging to the genera *Saccharomyces*, *Kluyveromyces*, *Hansenula* or *Pichia*, or moulds such as those belonging to the genera *Aspergillus* or *Trichoderma*.

[0034] Preferred hosts for use in connection with the present invention are the lower eukaryotic moulds and yeasts.

[0035] Techniques for synthesising genes, incorporating them into hosts and expressing genes in hosts are well known in the art and the skilled person would readily be able to put the invention into effect using common general knowledge.

[0036] Methods for producing antibody fragments or functionalised fragments thereof derived from the heavy chain immunoglobulin of *Camelidae* using a transformed lower eukaryotic host are described, for example in patent application WO 94/25591 and such techniques may suitably be applied to prepare constructs according to the present invention.

[0037] Proteins according to the invention may be recovered and purified using conventional techniques such as affinity chromatography, ion exchange chromatography or gel filtration chromatography.

[0038] The activity of the multivalent binding proteins according to the invention may conveniently be measured by standard techniques known in the art such as enzyme-linked immunoadsorbant assay (ELISA), radioimmune assay (RIA) or by using biosensors.

[0039] The following examples are produced by way of illustration only.

[0040] Techniques used for the manipulation and analysis of nucleic acid materials were performed as described in Sambrook et al, Molecular Cloning, Cold Spring Harbor Press, New York, 2nd Ed., (1989) unless otherwise indicated.

[0041] Restriction sites are underlined.

HC-V denotes heavy chain variable domain.

EXAMPLES

Example 1 Self Assembling Llama Bi-heads Containing Linker Peptides on Latex to Assay hCG

1.1 Construction of Llama Bi-heads with Various Linkers

a) Induction of humeral immune responses in llama

[0042] Male llamas were immunised with a water in oil emulsion (1:9 V/V, antigen in water: Specol (Bokhout et al, Vet. Immunol. Immunopath., 2:, 491-500 (1981)) subcutaneously and intramuscularly. Per immunisation site 0.75-1.5 ml water in oil emulsion was inoculated containing 100:g antigen. The antigens used were: hCG (Sigma), azo-dye RR6 (ICI) which was coupled to BSA via its reactive triazine group. Immunisations were performed according to the following time table: The second immunisation was performed three weeks after the first. The third was performed two weeks after the second immunisation. The immune response was followed by antigen specific ELISAs.

[0043] The anti-RR-6 response was measured by using Nunc Covalink plates, which were coated with the azo-dye. After incubation with (diluted) serum samples, the bound llama antibodies were detected via a incubation with polyclonal rabbit-anti-llama antiserum (obtained via immunising rabbits with llama immunoglobulins which were purified via ProtA and ProtG columns; ID-DLO), followed by an incubation with swine-anti-rabbit immunoglobulins (Dako) conjugated with alkaline phosphatase. Finally the alkaline phosphatase enzyme-activity was determined after incubation with p-nitro-phenyl phosphate and the optical density was measured at 405nm. The anti-hCG response, was measured in essentially the same way using Nunc maxi-sorb plates coated with hCG.

b) Cloning, expressing and screening of llama HC-V fragments

i) Isolation of gene fragments encoding llama HC-V domains

[0044] From an immunised llama a blood sample of about 200ml was taken and an enriched lymphocyte population was obtained via Ficoll (Pharmacia) discontinuous gradient centrifugation. From these cells, total RNA was isolated by acid guanidium thiocyanate extraction (e.g. via the method described by Chomczynski and Sacchi, Analytical Biochemistry, 162: 156-159 (1987). After first strand cDNA synthesis (e.g. with the Amersham first strand cDNA kit), cDNA fragments encoding HC-V fragments and part of the long or short hinge region were amplified by PCR using specific primers:

*Pst*I

V_H - 2B 5'-AGGTSMARCTGCAGSAGTCWGG-3' (SEQ. ID NO. 6)

S = C and G, M = A and C, R = A and G, W = A and T,

*Hind*III

Lam-07 5'-AACAGTTAAGCTTCCGCTTGC GGCCGCGGAGCTGGGGTCTTCGCTGTGGTGCG-3' (SEQ. ID NO. 7)
(short hinge)

*Hind*III

Lam-08 5'-AACAGTTAAGCTTCCGCTTGC GGCCGCGTGGTTGTGGTTTGGTGTCTTGGGTT-3' (SEQ. ID NO. 8)
(long hinge)

[0045] Upon digestion of the PCR fragments with *Pst*I (coinciding with codon 4 and 5 of the HC-V domain, encoding the amino acids L-Q) and *Bst*EII (located at the 3'-end of the HC-V gene fragments, coinciding with the amino acid sequence Q-V-T), the DNA fragments with a length between 300 and 400bp (encoding the HC-V domain, but lacking the first three and the last three codons) were purified via gel electrophoresis and isolation from the agarose gel.

ii) Construction of *Saccharomyces cerevisiae* expression plasmids encoding llama HC-V domains

[0046] Plasmids pUR4547 and pUR4548 are *Saccharomyces cerevisiae* episomal expression plasmids, derived from pSY1 (Harmsen et al., Gene, 125: 115-123, (1993)). From pSY1 the *Pst*I site, located in front of the GAL7 promoter was removed after partial digestion with *Pst*I, incubation with Klenow fragment and subsequent blunt end ligation. After transformation the desired plasmid could be selected on the basis of restriction pattern analysis. Subsequently, the *Bst*EII site in the Leu2 selection marker was removed by replacing the about 410bp *Afl*II/*Pfl*MI fragment with a corresponding fragment in which the *Bst*EII site was removed via a three step PCR mutagenesis, using the primers:

PCR-A:

[0047]

*Pfl*MI

BOLI 1 5'-GGGAATTCCAATAGGTGGTTAGCAATCG (SEQ. ID NO. 9)

(*Bst*EII)

BOLI 4 5'-GACCAACGTGGTCGCCTGGCAAACG (SEQ. ID NO. 10)

PCR-B:

[0048]

5 (BstEII)
BOLI 3 5'-CGTTTGGCCAGGCGACCGTGGTC (SEQ. ID NO. 11)

10 AfIII
BOLI 2 5'-CCCCAAGCTTACATGGTCTTAAGTTGGCGT (SEQ. ID NO. 12)

[0049] PCR-A was performed with primers BOLI 1 and BOLI 4 and resulted in an about 130bp fragment with the PflMI restriction site at the 3'-end and the inactivated BstEII site at the 5'-end. PCR-B was performed with primers BOLI 2 and BOLI 3 and resulted in an about 290bp fragment with the AflII site at the 5'-end. The third PCR was with the fragments obtained from reaction A and B, together with the primers BOLI 1 and BOLI 2.

[0050] Finally, the about 1.8kb SacI-HindIII fragment was replaced with synthetic fragments, having sequences as presented below, resulting the plasmids pUR4547 and pUR4548, respectively.

20 - SacI/HindIII fragment of pUR4547

[0051]

25 SacI (SEQ. ID NO. 13)
GAGCTCATCACACAAACAAACAAAACAAAATGATGCTTTTGCAAGCCTTCCCTT
1 -----+-----+-----+-----+-----+----- 54
CTCGAGTAGTGTGTTTGTGTTTGTGTTTACTACGAAAACGTTCCGGAAGGGAA
30 M M L L Q A F L F
|→ SUC2 ss (SEQ. ID NO. 14)

PstI
35 TTCCTTTTGGCTGGTTTTGCAGCCAAAATATCTGCGCAGGTGCAGCTGCAGG
55-----+-----+-----+-----+-----+----- 105
AAGGAAAACCGACCAAAACGTCGGTTTTATAGACGCGTCCACGTCGACGTCC
L L A G F A A K I S A Q V Q L Q E
40 |→

BstEII HindIII
106-----+-----+-----+-----+-----+----- 155
45 AGTCATAATGAGGGACCCAGGTCACCGTCTCCTCATAATGACTTAAGCTT
TCAGTATTACTCCCTGGGTCCAGTGGCAGAGGAGTATTACTGAATTCGAA
E S * * G T Q V T V S S * *
HC-V cassette ←|

50 and

55

- *SacI*/*HindIII* fragment of pUR4548

[0052]

5

SacI (SEQ. ID NO. 15)
 GAGCTCATCACACAAACAAACAAACAAATGATGCTTTTGCAAGCCTTCCTTT
 1 -----+-----+-----+-----+-----+----- 54
 10 CTCGAGTAGTGTGTTTGTGTTTGTGTTTACTACGAAAACGTTTCGGAAGGAAA
 M M L L Q A F L F
 |→ SUC2 ss (SEQ. ID NO. 16)

15

PstI
 TCCTTTTGGCTGGTTTTGCAGCCAAATATCTGCGCAGGTGCAGCTGCAGG
 55-----+-----+-----+-----+-----+----- 105
 AGGAAAACCGACCAAAACGTCGGTTTTATAGACGCGTCCACGTCGACGTCC
 L L A G F A A K I S A Q V Q L Q E
 20 |→

25

BstEII
 AGTCATAATGAGGGACCCAGGTCACCGTCTCCTCAGAACAAAACTCATC
 106-----+-----+-----+-----+-----+----- 155
 TCAGTATTACTCCCTGGGTCCAGTGGCAGAGGAGTCTTGTTTTGAGTAG
 S * * G T Q V T V S S E Q K L I
 HC-V cassette ←|→ myc tail

30

HindIII
 TCAGAAGAGGATCTGAATTAATGACTTAAGCTT
 156-----+-----+-----+-----+-----+----- 188
 AGTCTTCTCCTAGACTTAATTACTGAATTCGAA
 S E E D L N * *
 ←|

40

[0053] Both plasmids contain the GAL7 promoter and PGK terminator sequences as well as the invertase (SUC2) signal sequence. In both plasmids the DNA sequence encoding the SUC2 signal sequence is followed by the first 5 codons, (encoding Q-V-Q-L-Q) of the HC-V domain (including the *Bst*II site), a stuffer sequence, the last six codons (encoding Q-V-T-V-S-S) of the HC-V domain. In pUR4547, this is followed by two stop codons, an *A*III and *Hind*III site. In pUR4548, this sequence is followed by eleven codons encoding the myc-tag, two stop codons, an *A*III and *Hind*III site.

[0054] Plasmids pUR4547 and pUR4548 were deposited under the Budapest Treaty at the Centraal Bureau voor Schimmelcultures, Baarn on 18th August 1997 with deposition numbers: CBS 100012 and CBS 100013, respectively. In accordance with Rule 28(4) EPC, or a similar arrangement from a state not being a contracting state of the EPC, it is hereby requested that a sample of such deposit, when requested, will be submitted to an expert only.

[0055] Upon digesting pUR4548 with *Pst*I and *Bst*EII, the about 6.4kb vector fragment was isolated and ligated with the *Pst*I-*Bst*EII fragments of about 350bp obtained as described above. After transformation of *S. cerevisiae*, via electroporation, transformants were selected from minimal medium agar plates (comprising 0.7% yeast nitrogen base, 2% glucose and 2% agar, supplemented with the essential amino acids and bases).

iii) Screening for antigen specific HC-V domains

[0056] For the production of llama HC-V fragments with myc-tail, individual transformants were grown overnight in selective minimal medium (comprising 0.7% yeast nitrogen base, 2% glucose, supplemented with the essential amino acids and bases) and subsequently diluted ten times in YPGal medium (comprising 1% yeast extract, 2% bacto pepton and 5% galactose). After 24 and 48 hours of growth, the culture supernatant of the colonies was analysed by ELISA for the presence of HC-V fragments which specifically bind to the antigens hCG, RR6 in essential the same way as described above. In this case, however, the presence of specifically bound HC-V fragments was detected by incubation with monoclonal anti-myc antibodies, followed by incubation with poly-clonal rabbit-anti-mouse conjugate with alkaline phosphatase. In this way a number of anti-hCG and anti-RR6 HC-V fragments were isolated, which are:

anti-RR6:

R9 pUR4640 (see Figure 1) (SEQ. ID NO. 17, 18)

anti-hCG (alpha unit):

H14 pUR4601 (see Figure 2) (SEQ. ID NO. 19, 20)

c) Production of llama HC-V biheads by *S. cerevisiae*

i) Construction of episomal expression plasmids encoding anti-hCG/anti-RR6 bispecific biheads

[0057] In the anti-hCG HC-V fragment H14 (anti-alpha-subunit), the *Pst*I site was removed and a *Xho*I site was introduced via PCR, using the primers:

MPG158WB

5'-GAATTAAGCGGCCGCCAGGTGAACTGCTCGAGTCWGGGGGA-3' (SEQ. ID NO. 21)

and

MPG159WB

3'-CCCTGGGTCCAGTGGCAGAGGAGTGGCAGAGGAGTCTTGT-5' (SEQ. ID NO. 22)

[0058] In this way the sequence:

CAG GTC CAG CTG CAG GAG TCT GGG (SEQ. ID NO. 23)
Q V Q L Q E S G

became

CAG GTG AAA CTG CTC GAG TCW GGG (SEQ. ID NO. 24)
Q V K L L E S G

5

10

20

25

40

35

40

45

50

10

MVaJA

5' *Bst*EII *Xba*I *Dra*III *Pst*I *Hind*III
 5' GTCACCGTCTCTAGATGGCCACCAGGTGCAGCTGCAGGAGTCAACTTA 3' (SEQ. ID NO. 29)

MVbJA

3' GCAGAGATCTACCGGTGGTCCACGTCGAGCTCCTCAGTTGAATTCCA 5'
 (SEQ. ID NO. 30)

15 [0064] This resulted in pSJ7a. In this plasmid the about 20 bp *Pst*I-*Hind*III fragment was replaced with the about 370 bp *Pst*I-*Hind*III fragment encoding the anti-RR6 HC-V fragment R9 and with the myc-tail of pUR4G40 (see Example 1 c(i)) and resulting in pSJ7b.

[0065] Upon digesting plasmid pSJ7b with *Xba*I and *Dra*III the about 7 kb vector fragment was ligated with five synthetic oligo nucleotide linker fragments presented below:

20

MV01JA 5' CTAGTGGTACTTCCGGTCCCAG 3' (SEQ. ID NO. 31)

25 MV02JA 3' ACCATGAAGGCCAAGG 5' (SEQ. ID NO. 32)

S G T S G S Q

30 MV03JA 5' CTAGTTCTTCATCTGCTTCTGCCTCTTCAGCCCAG 3' (SEQ. ID NO. 33)

35 MV04JA 3' AAGAAGTAGACGAAGACGGAGAAGTCGG 5' (SEQ. ID NO. 34)

S S S S A S A S S A Q

40 MV05JA 5' CTAGTGGTCTCCAGGTTCAACAGGTCAG 3' (SEQ. ID NO. 35)

MV06JA 3' ACCAAGAGGTCCAAGTGGTCCA 5' (SEQ. ID NO. 36)

45

S G S P G S P G Q

50

55

MV07JA 5' CTAGTGCTACTACAACTGGTTCTTCACCAGGTCCAACCTCAG 3' (SEQ. ID NO. 37)

MV08JA 3' ACGATGATGTTGACCAAGAAGTGGTCCAGGTGA 5' (SEQ. ID NO. 38)

S A T T T G S S P G P T Q

MV09JA 5' CTAGTGCTAATCATTCTGGTAATGCTTCTCAG 3' (SEQ. ID NO. 39)

MV10JA 3' ACGATTAGTAAGACCATTACGAAGA 5' (SEQ. ID NO. 40)

S A N H S G N A S Q

[0066] The oligonucleotide linker fragments encode the last amino acid of the N-terminal HC-V fragment (S) and the first amino acid of the C-terminal HC-V fragment, intersected by the connecting linker peptide. This resulted in plasmids pUR5330 to 5334, respectively.

[0067] After transformation of *S. cerevisiae* with these plasmids, the production levels of the biheads were determined via Western blot analysis and a anti-hCG ELISA using anti-myc mAb for detection of the bound bihead (see Example 1 b(iii)). Production levels are presented in Table 2 below:

Table 2

Plasmid	Linker	Production level (mg/l)
pUR4619	None	11
pUR5330	S-G-T-S-G-S-Q	36
pUR5331	S-S-S-S-A-S-A-S-S-A-Q	49
pUR5332	S-G-S-P-G-S-P-G-Q	33
pURS333	S-A-T-T-T-G-S-S-P-G-P-T-Q	56
pUR5334	S-A-N-H-S-G-N-A-S-Q	51

[0068] The production levels of the biheads in which the two HC-V domains are separated by a linker peptide (consisting of between 5 and 11 amino acids) were found to be 3 to 5 times higher as found for the bihead in which the two HC-V fragments are connected without a peptide linker.

[0069] Finally, the bispecificity of the biheads was demonstrated as follows:

[0070] PINs coated with hCG were incubated with (diluted) medium samples. Subsequently, the PINs were incubated with a RR6-alkaline phosphatase conjugate, in which the azo-dye RR6 was coupled to the alkaline phosphatase via its reactive triazine group. Finally, the alkaline phosphatase enzyme activity was determined after incubation of the PINs with p-nitro-phenyl phosphate and the optical density was measured at 405nm (see Figure 5).

1.2 Purification of Llama Bi-heads with Various Linkers from *S. cerevisiae* Culture Media

[0071] A 5 ml column of recombinant Protein A Fast Flow Sepharose (Amersham Pharmacia Biotech) was equilibrated by washing with 10 column volumes of wash buffer (10 mM potassium phosphate, pH 6), at a flow rate of 2 ml/min. The bi-head fermentation broth was loaded at 2 ml/min in an upwards direction. After loading, the column was washed with wash buffer until the OD₂₈₀ reached the baseline. Elution was carried out with a linear gradient of 0 - 40

mM citric acid pH 2.5 in the reverse direction, collecting 4 ml fractions into tubes containing 400 µl of a neutralising agent (1M Tris.Cl, pH 8.5) in order to minimise the effects of the acid. Peak fractions were checked for purity by running on a 12% SDS-PAGE Ready Gel (Bio-Rad) under standard denaturing conditions. Staining was with GelCode Blue (Pierce & Warriner). The fractions were concentrated using Macrosep centrifugal concentrators (3 kDa molecular weight cut-off, Pall Filtron Corp.) then buffer exchanged into 10mM potassium phosphate, pH 6 using PD-10 columns (Amersham Pharmacia Biotech). The final purity of the sample was determined by carrying out a UV scan from 400 - 220 nm and using the value at 280 nm to determine an accurate concentration. The samples were then aliquoted into vials, frozen, freeze dried and stored until required.

1.3 Preparation of a Reactive Red 6-Bovine Serum Albumin Conjugate

[0072] A solution of Reactive Red 6 (RR6) was made up at 10 mg/ml in phosphate buffered saline (PBS). A solution of bovine serum albumin (BSA) was made up at 10 mg/ml in PBS. 200 µl of the RR6 solution was added to 800 µl of the BSA solution and the resulting solution was mixed in an end over end rotary mixer for 2 hours at room temperature. RR6 that had conjugated to BSA was separated from free RR6 by addition of the reaction mixture (1 ml) to a PD10 column (Pharmacia) previously washed with 10 ml of PBS containing 0.1% sodium azide (PBSA). The column was then eluted by addition of PBSA (5 ml) and 1 ml aliquots were collected. The RR6-BSA conjugate eluted in fractions 4 and 5. These were pooled and the concentration of protein was determined using a BCA protein test and the concentration adjusted to 2 mg/ml with PBSA.

1.4 Adsorption of Latex with Reactive Red 6-Bovine Serum Albumin Conjugate.

[0073] Duke blue latex was adsorbed with the RR6-BSA conjugate as follows:

[0074] To 950 µl of 10 mM borate buffer, 0.01 % merthiolate, pH 8.5 (buffer B) a 50 µl aliquot of Duke blue latex (10 % solids) was added and mixed by inverting. The diluted latex was centrifuged at 8000 g for 10 minutes at room temperature, the supernatant removed and the pellet vortexed briefly. The pellet was resuspended in 900 µl of buffer B and to this 100 µl of the previously prepared RR6-BSA conjugate was added. The latex solution was sonicated for 10 s using a sonic probe. The solution containing the latex was mixed for 2 h at room temperature and then centrifuged (8000 g, 10 min at room temperature). The latex pellet was washed by resuspending in 1 ml of buffer B and centrifuged once more (8000 g, 10 min at room temperature). The pellet was then resuspended in 1 ml buffer B ready for use.

1.5 Analysis of Llama Bi-head Self Assembling on Reactive Red 6-Bovine Serum Albumin Adsorbed Latex

[0075] The llama bi-heads were tested by self assembling onto RR6-BSA adsorbed latex and detection of hCG in a rapid assay technology (RAT) format. This was performed by mixing the llama bi-head (5 µl of a 0.1 mg/ml solution) with RR6-BSA adsorbed latex (5 µl of 0.1 % solids) in 10 µl of PBSA to which hCG (5 µl of various concentrations) was added.

[0076] The resulting solution was added to the bottom of a nitrocellulose strip (6 mm wide x 30 mm long) on which a monoclonal antibody recognising hCG had been adsorbed by plotting in a line (2.5 mg/ml) mid way up the strip. The latex-bi-head-hCG solution was allowed to flow up the nitrocellulose strip by capillary action and the strip was then washed by applying PBSA (25 µl) to the bottom of the strip. The amount of latex, captured at the plotted antibody line on the nitrocellulose strip, was quantified by measuring the absorbance through the strip.

[0077] Figure 6 shows that the llama bi-heads with linkers 3, 4 and 5 gave the highest response in RAT assays. These linkers are structurally more ordered than the comparative examples, flexible linkers 2 and 6 and result in more hCG and more latex captured in the assay. The more ordered linkers promote the correct orientation of the binding domains to achieve more optimal binding than when no linker is used. Linker 3 is derived from CWP1 and Linker 5 from CBH1P.

[0078] Synthetic linkers with some order (linker 4 containing 2 proline residues) can offer increased sensitivity in assays than those with little order (linker 2). Figure 7 shows that the bi-head with linker 4 can detect lower amounts (50 mIU/ml) of hCG than the bi-head with linker 2 and, hence, give a more sensitive assay for hCG.

SEQUENCE LISTING

5 <110> UNILEVER PLC
UNILEVER N.V

<120> ANTIGEN BINDING PROTEINS

10 <130> T3077

<140>
<141>

<160> 40

15 <170> PatentIn Ver. 2.1

<210> 1
<211> 5
<212> PRT
20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER

25 <400> 1
Gly Thr Ser Gly Ser
1 5

<210> 2
<211> 9
30 <212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LINKER

35 <400> 2
Ser Ser Ser Ala Ser Ala Ser Ser Ala
1 5

40 <210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

45 <220>
<223> Description of Artificial Sequence:LINKER

<400> 3
Gly Ser Pro Gly Ser Pro Gly
1 5

50

<210> 4

55

EP 1 002 861 A1

5 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 4
 10 Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr
 1 5 10
 <210> 5
 <211> 8
 15 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:PRIMER
 20 <400> 5
 Ala Asn His Ser Gly Asn Ala Ser
 1 5
 <210> 6
 25 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:PRIMER
 30 <400> 6
 aggtsmarct gcagsagtcw gg 22
 <210> 7
 35 <211> 53
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:PRIMER
 40 <400> 7
 aacagttaag cttccgcttg cggccgcgga gctggggtct tcgctgtggt gcg 53
 <210> 8
 45 <211> 53
 <212> DNA
 <213> Artificial Sequence
 <220>
 50 <223> Description of Artificial Sequence:PRIMER
 <400> 8
 55

aacagttaag cttccgcttg cggccgctgg ttgtggtttt ggtgtcttgg gtt 53
 5 <210> 9
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 10 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 9
 gggaattcca ataggtggtt agcaatcg 28
 15 <210> 10
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 20 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 10
 gaccaacgtg gtcgcctggc aaaacg 26
 25 <210> 11
 <211> 26
 <212> DNA
 <213> Artificial Sequence
 30 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 11
 cgttttgccca ggcgaaccacg ttggtc 26
 35 <210> 12
 <211> 30
 <212> DNA
 <213> Artificial Sequence
 40 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 12
 cccaagctt acatggtctt aagtggcgt 30
 45 <210> 13
 <211> 155
 <212> DNA
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence:PLASMID
 55

EP 1 002 861 A1

CONSTRUCT

5 <220>
 <221> CDS
 <222> (3)..(140)

<400> 13
 ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala
 1 5 10 15

10 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95
 Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val
 20 25 30

15 cag ctg cag gag tca taa tga ggg acc cag gtc acc gtc tcc tca 140
 Gln Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser
 35 40 45

20 taatgactta agctt 155

<210> 14
 <211> 46
 <212> PRT
 <213> Artificial Sequence
 25 <223> Description of Artificial Sequence: PLASMID
 CONSTRUCT

<400> 14
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe
 1 5 10 15

30 Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln
 20 25 30

35 Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser
 35 40 45

40 <210> 15
 <211> 188
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PLASMID
 CONSTRUCT

45 <220>
 <221> CDS
 <222> (3)..(173)

50 <400> 15
 ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala
 1 5 10 15

55

EP 1 002 861 A1

5 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95
 Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val
 20 25 30

cag ctg cag gag tca taa tga ggg acc cag gtc acc gtc tcc tca gaa 143
 Gln Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser Glu
 35 40 45

10 caa aaa ctc atc tca gaa gag gat ctg aat taatgactta agctt 188
 Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn
 50 55

15 <210> 16
 <211> 57
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT

20 <400> 16
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe
 1 5 10 15

25 Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln
 20 25 30

30 Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser Glu Gln
 35 40 45

35 Lys Leu Ile Ser Glu Glu Asp Leu Asn
 50 55

40 <210> 17
 <211> 342
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT

50 <220>
 <221> CDS
 <222> (1)..(342)

55 <400> 17
 cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg gag 48
 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu
 1 5 10 15

tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc ggc 96
 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly
 20 25 30

ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg gtc 144
 Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val

EP 1 002 861 A1

	35	40	45	
5	gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg aag	192		
	Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys			
	50 55 60			
10	ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat ttg	240		
	Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu			
	65 70 75 80			
15	gaa atg aac agc ctg gaa cct gaa gac acg gcc gtt tat tac tgt tac	288		
	Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr			
	85 90 95			
20	act cac tac ttc aga tcc tac tgg ggt cag ggg acc cag gtc acc gtc	336		
	Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val			
	100 105 110			
25	tcc tca	342		
	Ser Ser			
	<210> 18			
	<211> 114			
	<212> PRT			
	<213> Artificial Sequence			
	<223> Description of Artificial Sequence: PLASMID			
	CONSTRUCT			
30	<400> 18			
	Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu			
	1 5 10 15			
35	Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly			
	20 25 30			
40	Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val			
	35 40 45			
45	Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys			
	50 55 60			
50	Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu			
	65 70 75 80			
55	Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr			
	85 90 95			
	Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val			
	100 105 110			
	Ser Ser			
	<210> 19			
	<211> 351			
	<212> DNA			
	<213> Artificial Sequence			

EP 1 002 861 A1

<220>
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 5
 <220>
 <221> CDS
 <222> (1)..(351)
 10
 <400> 19
 cag gtg cag ctg cag gag tca ggg gga gga ttg gtg cag gcg ggg ggc 48
 Gln Val Gln Leu Ser Gln Gly Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15
 tct ctg aga ctc tcc tgt gca gcc tct gga cgc acc ggc agt acg tat 96
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr
 20 25 30
 gac atg ggc tgg ttc cgc cag gct cca ggg aag gag cgt gag tct gta 144
 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val
 35 40 45
 gca gct att aac tgg gat agt gcg cgc aca tac tat gca agc tcc gtg 192
 Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val
 50 55 60
 agg ggc cga ttc acc atc tcc aga gac aac gcc aag aag acg gtg tat 240
 Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
 65 70 75 80
 ctg caa atg aac agc ctg aaa cct gag gac acg gcc gtt tat acc tgt 288
 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys
 85 90 95
 ggc gcg ggg gaa ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag 336
 Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln
 100 105 110
 gtc acc gtc tcc tca 351
 Val Thr Val Ser Ser
 115
 40
 <210> 20
 <211> 117
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 45
 <400> 20
 Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr
 20 25 30
 Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val
 55

EP 1 002 861 A1

35 40 45

5 Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val
50 55 60

Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
65 70 75 80

10 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys
85 90 95

Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln
100 105 110

15 Val Thr Val Ser Ser
115

<210> 21
<211> 43
20 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PRIMER

25 <400> 21
gaattaagcg gccgcccagg tgaaactgct cgagtcwggg gga 43

<210> 22
<211> 42
30 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PRIMER

35 <400> 22
ccctgggtcc agtggcagag gagtggcaga ggagtcttgt tt 42

<210> 23
<211> 24
40 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PRIMER

45 <400> 23
caggtccagc tgcaggagtc tggg 24

<210> 24
<211> 24
50 <212> DNA
<213> Artificial Sequence

55

EP 1 002 861 A1

```

<220>
<223> Description of Artificial Sequence:PRIMER

5      <400> 24
      caggtgaaac tgctcgagtc wggg                                24

10     <210> 25
      <211> 55
      <212> DNA
      <213> Artificial Sequence

15     <220>
      <223> Description of Artificial Sequence:LINKER;DOUBLE
          STRANDED

20     <220>
      <221> CDS
      <222> (2) .. (55)

      <400> 25
      g gtc acc gtc tcc tca cag gtg cag ctg cag gag tca ctg taa tga ctt 49
        Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu          Leu
          1              5              10              15

25     aag ctt                                55
      Lys Leu

30     <210> 26
      <211> 18
      <212> PRT
      <213> Artificial Sequence
      <223> Description of Artificial Sequence:LINKER;DOUBLE
          STRANDED

35     <400> 26
      Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu          Leu
          1              5              10              15

      Lys Leu

40     <210> 27
      <211> 672
      <212> DNA
      <213> Artificial Sequence

45     <220>
      <223> Description of Artificial Sequence:PLASMID
          CONSTRUCT

50     <220>
      <221> CDS
      <222> (1) .. (672)

55

```

EP 1 002 861 A1

55

EP 1 002 861 A1

5 <210> 28
 <211> 224
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence: PLASMID
 CONSTRUCT

 <400> 28
 10 Leu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu
 1 5 10 15
 Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr Asp Met Gly Trp
 20 25 30
 15 Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn
 35 40 45
 Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe
 50 55 60
 20 Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn
 65 70 75 80
 Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu
 85 90 95
 25 Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser
 100 105 110
 Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly
 115 120 125
 30 Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly
 130 135 140
 Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
 145 150 155 160
 35 Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val
 165 170 175
 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
 180 185 190
 40 Leu Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys
 195 200 205
 Tyr Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr
 210 215 220
 45
 <210> 29
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 50
 <220>
 <223> Description of Artificial Sequence: SYNTHETIC
 55

INSERT

5 <400> 29
 gtcaccgtct ctagatggcc accaggtgca gctgcaggag tcaactta 48

10 <210> 30
 <211> 47
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence:SYNTHETIC
 INSERT

20 <400> 30
 gcagagatct accggtggtc cacgtcgagc tcctcagttg aattcga 47

25 <210> 31
 <211> 23
 <212> DNA
 <213> Artificial Sequence

30 <220>
 <223> Description of Artificial Sequence:LINKER

35 <400> 31
 ctagtggtac ttccggttcc cag 23

40 <210> 32
 <211> 16
 <212> DNA
 <213> Artificial Sequence

45 <220>
 <223> Description of Artificial Sequence:LINKER

50 <400> 32
 accatgaagg ccaagg 16

55 <210> 33
 <211> 35
 <212> DNA
 <213> Artificial Sequence

60 <220>
 <223> Description of Artificial Sequence:LINKER

65 <400> 33
 ctagttcttc atctgcttct gcctcttcag cccag 35

70 <210> 34
 <211> 28
 <212> DNA

<213> Artificial Sequence
 <220>
 5 <223> Description of Artificial Sequence:LINKER
 <400> 34
 aagaagtaga cgaagacgga gaagtcgg 28
 <210> 35
 <211> 29
 <212> DNA
 <213> Artificial Sequence
 <220>
 15 <223> Description of Artificial Sequence:LINKER
 <400> 35
 ctagtgggtc tccaggttca ccaggtcag 29
 <210> 36
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 25 <223> Description of Artificial Sequence:LINKER
 <400> 36
 accaagaggt ccaagtggtc ca 22
 <210> 37
 <211> 41
 <212> DNA
 <213> Artificial Sequence
 <220>
 35 <223> Description of Artificial Sequence:LINKER
 <400> 37
 ctagtgctac tacaactggg tcttcaccag gtccaactca g 41
 <210> 38
 <211> 34
 <212> DNA
 <213> Artificial Sequence
 <220>
 45 <223> Description of Artificial Sequence:LINKER
 <400> 38
 acgatgatgt tgaccaagaa gtggtccagg ttga 34
 <210> 39

55

5 <211> 32
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER

 10 <400> 39
 ctagtgctaa tcattctggt aatgcttctc ag 32

 15 <210> 40
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 20 <223> Description of Artificial Sequence:LINKER

 <400> 40
 acgattagta agaccattac gaaga 25

 25

 30

 35

 40

 45

 50

 55

SEQUENCE LISTING

5 <110> UNILEVER PLC
 UNILEVER N.V.
 <120> ANTIGEN BINDING PROTEINS
 <130> T3077
 <140>
 10 <141>
 <160> 45
 <170> PatentIn Ver. 2.1
 15 <210> 1
 <211> 5
 <212> PRT
 <213> Artificial Sequence
 <220>
 20 <223> Description of Artificial Sequence:LINKER
 <400> 1
 Gly Thr Ser Gly Ser
 1 5
 25 <210> 2
 <211> 9
 <212> PRT
 <213> Artificial Sequence
 <220>
 30 <223> Description of Artificial Sequence:LINKER
 <400> 2
 Ser Ser Ser Ala Ser Ala Ser Ser Ala
 1 5
 35 <210> 3
 <211> 7
 <212> PRT
 <213> Artificial Sequence
 <220>
 40 <223> Description of Artificial Sequence:LINKER
 <400> 3
 Gly Ser Pro Gly Ser Pro Gly
 1 5
 45 <210> 4
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 50 <220>
 <223> Description of Artificial Sequence:PRIMER
 <400> 4
 55

EP 1 002 861 A1

Ala Thr Thr Thr Gly Ser Ser Pro Gly Pro Thr
1 5 10

5
<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

10
<220>
<223> Description of Artificial Sequence:PRIMER

<400> 5
Ala Asn His Ser Gly Asn Ala Ser
1 5

15
<210> 6
<211> 22
<212> DNA
<213> Artificial Sequence

20
<220>
<223> Description of Artificial Sequence:PRIMER

<400> 6
aggtsmarct gcagsagtcw gg 22

25
<210> 7
<211> 53
<212> DNA
<213> Artificial Sequence

30
<220>
<223> Description of Artificial Sequence:PRIMER

<400> 7
aacagttaag cttccgcttg cggccgcgga gctggggtct tcgctgtggt gcg 53

35
<210> 8
<211> 53
<212> DNA
<213> Artificial Sequence

40
<220>
<223> Description of Artificial Sequence:PRIMER

<400> 8
aacagttaag cttccgcttg cggccgcttg ttgtggtttt ggtgtcttgg gtt 53

45
<210> 9
<211> 28
<212> DNA
<213> Artificial Sequence

50
<220>
<223> Description of Artificial Sequence:PRIMER

<400> 9
gggaattcca atagtggtt agcaatcg 28

55

EP 1 002 861 A1

5 <210> 10
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PRIMER

 10 <400> 10
 gaccaacgtg gtcgcctggc aaaacg 26

 15 <210> 11
 <211> 26
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PRIMER

 20 <400> 11
 cgttttgccg ggcgaccacg ttggtc 26

 25 <210> 12
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PRIMER

 30 <400> 12
 ccccaagctt acatggtctt aagttggcgt 30

 35 <210> 13
 <211> 155
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT

 40 <220>
 <221> CDS
 <222> (3)..(110) -

 <220>
 <221> CDS
 <222> (117)..(140)

 45 <220>
 <221> CDS
 <222> (147)..(155)

 50 <400> 13
 ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala
 1 5 10 15

 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95

 55

EP 1 002 861 A1

Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val
 20 25 30
 5
 cag ctg cag gag tca taatga ggg acc cag gtc acc gtc tcc tca taatga 146
 Gln Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser
 35 40
 ctt aag ctt 155
 Leu Lys Leu
 45
 10
 <210> 14
 <211> 36
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 15
 <400> 14
 Ala His His Thr Asn Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe
 1 5 10 15
 20
 Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln
 20 25 30
 Leu Gln Glu Ser
 35
 25
 <210> 15
 <211> 8
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 30
 <400> 15
 Gly Thr Gln Val Thr Val Ser Ser
 1 5
 35
 <210> 16
 <211> 3
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 40
 <400> 16
 Leu Lys Leu
 1
 45
 <210> 17
 <211> 188
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT
 50
 <220>
 55

EP 1 002 861 A1

5 <221> CDS
<222> (3)..(110)

<220>
<221> CDS
<222> (117)..(173)

10 <220>
<221> CDS
<222> (180)..(188)

<400> 17
ga gct cat cac aca aac aaa caa aac aaa atg atg ctt ttg caa gcc 47
Ala His His Thr Asn Lys Lys Gln Asn Lys Met Met Leu Leu Gln Ala
1 5 10 15

15 ttc ctt ttc ctt ttg gct ggt ttt gca gcc aaa ata tct gcg cag gtg 95
Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val
20 25 30

20 cag ctg cag gag tca taatga ggg acc cag gtc acc gtc tcc tca gaa 143
Gln Leu Gln Glu Ser Gly Thr Gln Val Thr Val Ser Ser Glu
35 40 45

caa aaa ctc atc tca gaa gag gat ctg aat taatga ctt aag ctt 188
Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Leu Lys Leu
50 55

25 <210> 18
<211> 36
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:PLASMID
CONSTRUCT

30 <400> 18
Ala His His Thr Asn Lys Lys Gln Asn Lys Met Met Leu Leu Gln Ala Phe
1 5 10 15

35 Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys Ile Ser Ala Gln Val Gln
20 25 30

Leu Gln Glu Ser
35

40 <210> 19
<211> 19
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence:PLASMID
CONSTRUCT

45 <400> 19
Gly Thr Gln Val Thr Val Ser Ser Glu Gln Lys Leu Ile Ser Glu Glu
1 5 10 15

Asp Leu Asn

50 <210> 20
<211> 3
<212> PRT

55


```

5      <213> Artificial Sequence
      <223> Description of Artificial Sequence:PLASMID
          CONSTRUCT

      <400> 20
      Leu Lys Leu
          1

10     <210> 21
      <211> 342
      <212> DNA
      <213> Artificial Sequence

15     <220>
      <223> Description of Artificial Sequence:PLASMID
          CONSTRUCT

      <220>
      <221> CDS
      <222> (1)..(342)

20     <400> 21
      cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg gag 48
      Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu
          1             5             10             15

25     tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc ggc 96
      Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly
          20             25             30

      ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg gtc 144
      Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
          35             40             45

30     gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg aag 192
      Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys
          50             55             60

35     ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat ttg 240
      Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu
          65             70             75             80

      gaa atg aac agc ctg gaa cct gaa gac acg gcc gtt tat tac tgt tac 288
      Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr
          85             90             95

40     act cac tac ttc aga tcc tac tgg ggt cag ggg acc cag gtc acc gtc 336
      Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
          100            105            110

      tcc tca 342
      Ser Ser

45     <210> 22
      <211> 114
      <212> PRT
      <213> Artificial Sequence
      <223> Description of Artificial Sequence:PLASMID
          CONSTRUCT

      <400> 22
      Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Glu

55

```

EP 1 002 861 A1

```

      1             5             10             15
5      Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly Gly
      20             25             30
      Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
      35             40             45
10     Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val Lys
      50             55             60
      Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu
      65             70             75             80
15     Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys Tyr
      85             90             95
      Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
      100            105            110
      Ser Ser

20     <210> 23
      <211> 351
      <212> DNA
      <213> Artificial Sequence

25     <220>
      <223> Description of Artificial Sequence:PLASMID
      CONSTRUCT

      <220>
      <221> CDS
      <222> (1)..(351)

30     <400> 23
      cag gtg cag ctg cag gag tca ggg gga gga ttg gtg cag gcg ggg ggc 48
      Gln Val Gln Leu Gln Glu Ser Gly Gly Leu Val Gln Ala Gly Gly
      1             5             10             15
35     tct ctg aga ctc tcc tgt gca gcc tct gga cgc acc ggc agt acg tat 96
      Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr
      20             25             30
      gac atg ggc tgg ttc cgc cag gct cca ggg aag gag cgt gag tct gta 144
      Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val
      35             40             45
40     gca gct att aac tgg gat agt gcg cgc aca tac tat gca agc tcc gtg 192
      Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val
      50             55             60
      agg ggc cga ttc acc atc tcc aga gac aac gcc aag aag acg gtg tat 240
      Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
      65             70             75             80
45     ctg caa atg aac agc ctg aaa cct gag gac acg gcc gtt tat acc tgt 288
      Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys
      85             90             95
50     ggc gcg ggg gaa ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag 336
      Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln
      100            105            110
55

```

gtc acc gtc tcc tca
Val Thr Val Ser Ser
115

5

<210> 24
<211> 117
<212> PRT
<213> Artificial Sequence
10 <223> Description of Artificial Sequence:PLASMID
CONSTRUCT

<400> 24
Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr
20 25 30
Asp Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val
35 40 45
20 Ala Ala Ile Asn Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val
50 55 60
Arg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
65 70 75 80
25 Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys
85 90 95
Gly Ala Gly Glu Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln
100 105 110
30 Val Thr Val Ser Ser
115

<210> 25
<211> 43
<212> DNA
35 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PRIMER

<400> 25
40 gaattaagcg gccgccagc tgaaactgct cgagtcwggg gga 43

<210> 26
<211> 42
<212> DNA
45 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PRIMER

<400> 26
50 ccctgggtcc agtggcagag gagtggcaga ggagtcttgt tt 42

<210> 27

```

5      <211> 24
      <212> DNA
      <213> Artificial Sequence

      <220>
      <223> Description of Artificial Sequence:PRIMER

      <400> 27
10     caggtccagc tgcaggagtc tggg                24

      <210> 28
      <211> 24
      <212> DNA
      <213> Artificial Sequence

15     <220>
      <223> Description of Artificial Sequence:PRIMER

      <400> 28
      caggtgaaac tgctcgagtc wggg                24

20

      <210> 29
      <211> 55
      <212> DNA
      <213> Artificial Sequence

25     <220>
      <223> Description of Artificial Sequence:LINKER;DOUBLE
          STRANDED

      <220>
      <221> CDS
30     <222> (2)..(40)

      <220>
      <221> CDS
      <222> (47)..(55)

35     <400> 29
      g gtc acc gtc tcc tca cag gtg cag ctg cag gag tca ctg taatga ctt 49
        Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu      Leu
          1             5             10

      aag ctt                55
      Lys Leu
40     15

      <210> 30
      <211> 13
      <212> PRT
      <213> Artificial Sequence
45     <223> Description of Artificial Sequence:LINKER;DOUBLE
          STRANDED

      <400> 30
      Val Thr Val Ser Ser Gln Val Gln Leu Gln Glu Ser Leu
          1             5             10

50

      <210> 31
55

```

5 <211> 3
 <212> PRT
 <213> Artificial Sequence
 <223> Description of Artificial Sequence:LINKER;DOUBLE
 STRANDED

 10 <400> 31
 Leu Lys Leu
 1

 15 <210> 32
 <211> 672
 <212> DNA
 <213> Artificial Sequence

 20 <220>
 <223> Description of Artificial Sequence:PLASMID
 CONSTRUCT

 <220>
 <221> CDS
 <222> (1)..(672)

 25 <400> 32
 ctc gag tca ggg gga gga ttg gtg cag gcg ggg ggc tct ctg aga ctc 48
 Leu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu
 1 5 10 15
 30 tcc tgt gca gcc tct gga cgc acc ggc agt acg tat gac atg ggc tgg 96
 Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr Asp Met Gly Trp
 20 25 30
 35 ttc cgc cag gct cca ggg aag gag cgt gag tct gta gca gct att aac 144
 Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn
 35 40 45
 40 tgg gat agt gcg cgc aca tac tat gca agc tcc gtg agg ggc cga ttc 192
 Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe
 50 55 60
 45 acc atc tcc aga gac aac gcc aag aag acg gtg tat ctg caa atg aac 240
 Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn
 65 70 75 80
 50 agc ctg aaa cct gag gac acg gcc gtt tat acc tgt ggc gcg ggg gaa 288
 Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu
 85 90 95
 55 ggt ggt act tgg gac tcc tgg ggc cag ggg acc cag gtc acc gtc tcc 336
 Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser
 100 105 110
 60 tca cag gtg cag ctg cag gag tca ggg gga ggc ttg gtg cag gct ggg 384
 Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly
 115 120 125
 65 gag tct ctg aaa ctc tcc tgt gca gcc tct gga aac acc ttc agt ggc 432
 Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly
 130 135 140
 70 ggc ttc atg ggc tgg tac cgc cag gct cca ggg aag cag cgc gag ttg 480
 Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
 145 150 155 160

 75

EP 1 002 861 A1

gtc gca acc att aat agt aga ggt atc aca aac tat gca gac ttc gtg 528
Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val
165 170 175

5 aag ggc cga ttc acc atc tcc aga gac aat gcc aag aag aca gtg tat 576
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
180 185 190

10 ttg gaa atg aac agc ctg gaa cct gaa gac acg gcc gtt tat tac tgt 624
Leu Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys
195 200 205

tac act cac tac ttc aga tcc tac tgg ggt cag ggg acc cag gtc acc 672
Tyr Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr
210 215 220

15 <210> 33
<211> 224
<212> PRT
<213> Artificial Sequence
20 <223> Description of Artificial Sequence: PLASMID
CONSTRUCT

<400> 33
Leu Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly Ser Leu Arg Leu
1 5 10 15

25 Ser Cys Ala Ala Ser Gly Arg Thr Gly Ser Thr Tyr Asp Met Gly Trp
20 25 30

Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Ser Val Ala Ala Ile Asn
35 40 45

30 Trp Asp Ser Ala Arg Thr Tyr Tyr Ala Ser Ser Val Arg Gly Arg Phe
50 55 60

Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr Leu Gln Met Asn
65 70 75 80

35 Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Thr Cys Gly Ala Gly Glu
85 90 95

Gly Gly Thr Trp Asp Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser
100 105 110

40 Ser Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Ala Gly
115 120 125

Glu Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Asn Thr Phe Ser Gly
130 135 140

45 Gly Phe Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu
145 150 155 160

Val Ala Thr Ile Asn Ser Arg Gly Ile Thr Asn Tyr Ala Asp Phe Val
165 170 175

50 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Lys Thr Val Tyr
180 185 190

Leu Glu Met Asn Ser Leu Glu Pro Glu Asp Thr Ala Val Tyr Tyr Cys
195 200 205

55

EP 1 002 861 A1

Tyr Thr His Tyr Phe Arg Ser Tyr Trp Gly Gln Gly Thr Gln Val Thr
210 215 220

5 <210> 34
<211> 48
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:SYNTHETIC
INSERT

<400> 34
gtcacgctct ctatagtgcc accaggtgca gctgcaggag tcaactta 48

15 <210> 35
<211> 47
<212> DNA
<213> Artificial Sequence

20 <220>
<223> Description of Artificial Sequence:SYNTHETIC
INSERT

<400> 35
gcagagatct accggtgggc cacgtcgagc tcctcagttg aattcga 47

25 <210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence:LINKER

<400> 36
ctagtggtag ttccggttcc cag 23

35 <210> 37
<211> 16
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence:LINKER

<400> 37
accatgaagg ccaagg 16

45 <210> 38
<211> 35
<212> DNA
<213> Artificial Sequence

50 <220>
<223> Description of Artificial Sequence:LINKER

<400> 38

55

ctagttcttc atctgcttct gcctcttcag cccag 35

5

<210> 39
 <211> 28
 <212> DNA
 <213> Artificial Sequence

10

<220>
 <223> Description of Artificial Sequence:LINKER

<400> 39
 aagaagtaga cgaagacgga gaagtcgg 28

15

<210> 40
 <211> 29
 <212> DNA
 <213> Artificial Sequence

20

<220>
 <223> Description of Artificial Sequence:LINKER

<400> 40
 ctagtggttc tccaggtca ccaggtcag 29

25

<210> 41
 <211> 22
 <212> DNA
 <213> Artificial Sequence

30

<220>
 <223> Description of Artificial Sequence:LINKER

<400> 41
 accaagaggt ccaagtggc ca 22

35

<210> 42
 <211> 41
 <212> DNA
 <213> Artificial Sequence

40

<220>
 <223> Description of Artificial Sequence:LINKER

<400> 42
 ctagtgctac tacaactggt tcttcaccag gtccaactca g 41

45

<210> 43
 <211> 34
 <212> DNA
 <213> Artificial Sequence

50

<220>
 <223> Description of Artificial Sequence:LINKER

<400> 43
 acgatgatgt tgaccaagaa gtggtccagg ttga 34

55

<210> 44

5 <211> 32
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER

10 <400> 44
 ctagtgctaa tcattctggt aatgcttctc ag 32

15 <210> 45
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence:LINKER

20 <400> 45
 acgattagta agaccattac gaaga 25

25

Claims

- 30 1. Use of a polypeptide group, the amino acid sequence of which group confers restricted conformational flexibility, as a linking group to link binding units in a multivalent binding protein.
2. Use according to claim 1 wherein the polypeptide linking group comprises from 4 to 30 amino acid residues.
- 35 3. Use according to claim 1 or 2 wherein the linking group comprises one or more proline residues.
4. Use according to claim 1 or 2 wherein the linking group comprises an amino acid sequence selected from:
- S-S-S-A-S-A-S-S-A,
 G-S-P-G-S-P-G, or
 A-T-T-T-G-S-S-P-G-P-T.
- 40
5. A multivalent binding protein comprising a plurality of binding units linked by means of intervening polypeptide linker groups, the amino acid sequence of which linker group confers restricted conformational flexibility.
- 45 6. A protein according to claim 5 wherein the binding units comprise heavy chain variable domains derived from an immunoglobulin naturally devoid of light chains.
7. A protein according to claim 5 or claim 6 wherein the antigen binding units comprise heavy chain variable domains derived from a Camelid immunoglobulin.
- 50 8. A protein according to any one of claims 5 to 7 comprising a bivalent antigen binding protein.
9. A protein according to any one of claims 5 to 8 wherein the linker group comprises from 4 to 30 amino acid residues.
- 55 10. A protein according to any one of claims 5 to 9 wherein the linker group comprises one or more proline residues.

11. A protein according to any one of claims 5 to 9 wherein the linker group comprises an amino acid sequence selected from:

5 S-S-S-A-S-A-S-S-A,
G-S-P-G-S-P-G, or
A-T-T-T-G-S-S-P-G-P-T.

12. Nucleotide sequences encoding for a multivalent binding protein of any one of claims 5 to 11.

10 13. An expression vector comprising a nucleotide sequence according to claim 12.

14. A host cell transformed with a vector according to claim 13.

15

20

25

30

35

40

45

50

55

PstI

CAGGTGCAGCTGCAGGAGTCAGGGGAGGCTTGGTGCAGGCTGGGAGTCTCTGAAACTCTCCTGTGCAGCCTCTGGAAACACCTTCAGT
 1 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 90
 GTCCACGTCGACGTCTCAGTCCCCCTCCGAACCACGTCCGACCCCTCAGAGACTTTGAGAGGACACGTCCGAGACCTTTGTGGAAGTCA
 Q V Q L Q E S G G G L V Q A G E S L K L S C A A S G N T F S
 [-> CDR I

KpnI

GCGCGCTTCATGGCTGGTACCGCCAGGCTCCAGGGAAGCAGCGGAGTTGGTCGCAACATTAAATAGTAGAGGTATCACAACTATGCA
 91 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 180
 CCGCCGAAGTACCGACCATGGCGGTCCGAGGTCCCTTCGTGCGGCTCAACCAGCGTTGGTAATTATCATCTCCATAGTGTGTTGATACGT
 G G F M G W Y R Q A P G K Q R E L V A T I N S R G I T N Y A
 <-) [-> CDR II

EagI

GACTTCGTGAAGGGCCGATTACCATCTCCAGAGACAATGCCAAGAAGACAGTGTATTTGGAATGAACAGCCTGGAACCTGAAGACACG
 181 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 270
 CTGAAGCACTTCCCGCTAAGTGGTAGAGTCTCTGTTACGGTTCTTCTGTCACATAAACCTTTACTTGTGCGACCTTGGACTTCGTGTC
 D F V K G R F T I S R D N A K K T V Y L E M N S L E P E D T
 , <-)

BstEII

GCCGTTTATTACTGTTACACTCACTACTTCAGATCCTACTGGGTCAGGGGACCCAGGTCACCGTCTCCTCA
 271 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 342
 CCGCAAATAATGACAATGTGAGTGATGAAGTCTAGGATGACCCAGTCCCCTGGGTCAGTGGCAGAGGAGT
 A V Y Y C Y T H Y F R S Y W G Q G T Q V T V S S
 [-> CDR III <-)

Figure 1.

PstI

CAGGTGCAGTCGACGAGTCAGGGGAGGATTGGTGCAGGCGGGGGCTCTCTGAGACTCTCCTGTGCAGCCTCTGGACGCACCGGCAGT
 1 -----+-----+-----+-----+-----+-----+-----+-----+ 90
 GTCCACGTCGACGTCCTCAGTCCCCCTCCTAACCAGTCCGCCCCCGAGAGACTCTGAGAGGACACGTCGGAGACCCTGCGTGGCCGTCA
 Q V Q L Q E S G G G L V Q A G G S L R L S C A A S G R T G S

EagI

ACGTATGACATGGGCTGGTTCGCCAGGCTCCAGGGAAGAGCGTGAGTCTGTAGCAGCTATTAACTGGGATAGTGCAGGCACATACTAT
 91 -----+-----+-----+-----+-----+-----+-----+ 180
 TGCATACTGTACCCGACCAAGGCGGTCCGAGGTCCCTTCCTCGCACTCAGACATCGTCGATAATTGACCCCTATCACGCGCGTGATGATA
 T Y D M G W F R Q A P G K E R E S V A A I N W D S A R T Y Y
 1-> CDR I <-1 1-> CDR II

EagI

GCAAGCTCCGTGAGGGGCGATTCCACCATCTCCAGAGACAACGCCAAGAAGACGGTGTATCTGCAAATGAACAGCCTGAAACCTGAGGAC
 181 -----+-----+-----+-----+-----+-----+-----+ 270
 CGTTCGAGGCACTCCCGGCTAAGTGGTAGAGGTCTCTGTTGGGTCTCTGCCACATAGACGTTTACTTGTGGGACTTTGGACTCCTG
 A S S V R G R F T I S R D N A K K T V Y L Q M N S L K P E D
 <-1

BstEII

ACGGCCGTTTATACCTGTGGCGCGGGGAAGGTGGTACTTGGGACTCCTGGGGCCAGGGGACCCAGGTCACCGTCTCCTCA
 271 -----+-----+-----+-----+-----+-----+-----+ 351
 TGCCGGCAAATATGGACACCGCGCCCTTCCACCATGAACCTGAGGACCCCGGTCCCTGGGTCCAGTGGCAGAGGAGT
 T A V Y T C G A G E G G T W D S W G Q G T Q V T V S S
 1-> CDR III <-1

Figure 2.




Figure 3.

XhoI
 1 CTGAGTCAGGGGAGGATTGGTGCAGGCGGGGGCTCTCTGAGACTCTCCTGTGCGCCTCTGGACGCACCGGCAGTACGTATGACATG 90
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 GAGCTCAGTCCCCCTCCTAACACGTCGCGCCCCGAGAGACTCTGAGAGGACACGTCGGAGACCTGCGTGGCCGTCATGCACTACTGTAC
 L E S G G G L V Q A G G S L R L S C A A S G R T G S T Y D M
 1-> CDR I

91 GGCTGGTTCGCCAGGCTCCAGGGAAGGAGCGTGAGTCTGTAGCAGCTATTAACTGGGATAGTCCGCGCACATACTATGCAAGCTCCGTG 180
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 CCGACCAAGGCGGTCCGAGGTCCCTTCTCGCACTCAGACATCGTCGATAATTGACCCATACGCGCGGTATGATACGTTCCGAGGCAC
 G W F R Q A P G K E R E S V A A I N W D S A R T Y Y A S S V
 <-1 1-> CDR II

EagI
 181 AGGGGCCGATTACCATCTCCAGAGACAACGCCAAGAAGACGGTGATCTGCAATGAACAGCCTGAAACCTGAGGACACGGCCGTTTAT 270
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 TCCCCGGCTAAGTGGTAGAGGTCTCTGTTGCGGTTCTTCTGCCACATAGACGTTTACTTGTGCGGACTTTGGACTCCTGTGCGCGCAATA
 R G R F T I S R D N A K K T V Y L Q M N S L K P E D T A V Y
 <-1

BstEII ↓ PstI
 271 ACCTGTGGCGCGGGGAAGGTGGTACTTGGGACTCCTGGGCGCAGGGGACCCAGGTACCGTCTCCTCACAGGTGCAGCTGCAGGAGTCA 360
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 TGGACACCGCGCCCTTCCACCATGAACCTGAGGACCCCGGTCCCTGGGTCCAGTGGCAGAGGAGTGTCCAGCTCGACGTCCTCAGT
 T C G A G E G T W D S W G Q G T Q V T V S S Q V Q L Q E S
 1-> CDR III <-1

KpnI
 361 GGGGGAGGCTTGGTGCAGGCTGGGGAGTCTCTGAAACTCTCCTGTGCGCCTCTGGAACACCTTCAGTGGCGGCTTCATGGGCTGGTAC 450
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 CCCCCCGCAACACGTCGACCCCTCAGAGACTTTGAGAGGACACGTCGGAGACCTTTGTGGAAGTCACCGCCGAAGTACCGGACCATG
 G G G L V Q A G E S L K L S C A A S G N T F S G G F M G W Y
 1-> CDR I <-1

451 CGCCAGGCTCCAGGGAAGCAGCGGAGTGGTGCACACCATTAATAGTAGAGGTATCACAACTATGCAGACTTCGTGAAGGGCCGATTC 540
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 GCGGTCCGAGGTCCCTTCGTGCGGCTCAACCAGCGTTGGTAATTATCATCTCCATAGTGTGATAGTCTGAAGCACTTCCCGGCTAAG
 R Q A P G K Q R E L V A T I N S R G I T N Y A D F V K G R F
 1-> CDR II <-1

EagI
 541 ACCATCTCCAGAGACAATGCCAAGAAGACAGTGTATTGGAATGAACAGCCTGGAACCTGAAGACACGGCCGTTTATTACTGTTACACT 630
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 TGGTAGAGGTCTCTGTTACGGTTCTTCTGTACATAAACCTTTACTTGTGCGGACCTTGGACTTCTGTGCGCGCAATAATGACAATGTGA
 T I S R D N A K K T V Y L E M N S L E P E D T A V Y Y C Y T

BstEII
 631 CACTACTTCAGATCCTACTGGGGTCAGGGGACCCAGGTACCC 672
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+
 GTGATGAAGTCTAGGATGACCCAGTCCCTGGGTCCAGTGG
 H Y F R S Y W G Q G T Q V T
 1-> CDR III <-1

Figure 4.





Figure 5.




Figure 6.




Figure 7.



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 3118

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
X	WO 93 02198 A (TECHNICAL RESEARCH CENTRE OF FINLAND) 4 February 1993 (1993-02-04) * page 11 - page 20 * * figures 2,4 * * claims *	1-5,8-14	C12N15/11 C07K19/00 C07K16/46 C12N1/19 C12N15/81
Y	---	6,7	
Y	H. HOOGENBOOM: "Mix and match: Building manifold binding sites." NATURE BIOTECHNOLOGY, vol. 15, no. 2, February 1997 (1997-02), pages 125-126, XP002110046 New York, NY, USA * page 126, right-hand column, line 30 - line 39 * * figure 1 *	6,7	
X	M. SRISODSUK ET AL.: "Role of the interdomain linker peptide of Trichoderma reesei cellobiohydrolase I in its interaction with crystalline cellulose." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 28, 5 October 1993 (1993-10-05), pages 20756-20761, XP002112074 Baltimore, MD, USA * abstract * * figure 1 *	1-5,9-14	TECHNICAL FIELDS SEARCHED C07K
X	P. HOLLIGER ET AL.: "Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody." PROTEIN ENGINEERING, vol. 9, no. 3, March 1996 (1996-03), pages 299-305, XP002112075 Oxford, GB * abstract * * figure 1 *	1,2,5,8,9,12-14	

-/--			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	12 August 1999	Nooij, F	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons --- & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03/82 (P/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 3118

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
X	A. PLÜCKTHUN ET AL.: "New protein engineering approaches to multivalent and bispecific antibody fragments." IMMUNOTECHNOLOGY, vol. 3, no. 2, June 1997 (1997-06), pages 83-105, XP004088466 Amsterdam, NL * page 98, right-hand column, line 27 - line 46 * * figure 6E *	1,2,5,8,9	
X	P. PORTOGHESE ET AL.: "Synthesis and opioid antagonist potencies of naltrexamine bivalent ligands with conformationally restricted spacers." JOURNAL OF MEDICINAL CHEMISTRY, vol. 29, no. 9, September 1986 (1986-09), pages 1650-1653, XP002112076 Washington, DC, USA * abstract * * figure 2 *	1,2,5,9	
A	K. ALFTHAN ET AL.: "Properties of a single-chain antibody containing different linker peptides." PROTEIN ENGINEERING, vol. 8, no. 7, July 1995 (1995-07), pages 725-731, XP002112077 Oxford, GB * abstract * * figure 1A *	1-5,9-11	
A	WO 94 13804 A (CAMBRIDGE ANTIBODY TECHNOLOGY LTD. & MEDICAL RESEARCH COUNCIL) 23 June 1994 (1994-06-23) * examples * * claims *	1-14	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 August 1999	Examiner Nooij, F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (p04c01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 30 3118

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION
A	WO 97 14719 A (UNILEVER NV) 24 April 1997 (1997-04-24) * examples * * claims * -----	1-14	
			TECHNICAL FIELDS SEARCHED
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 12 August 1999	Examiner Nooij, F
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03/82 (P04/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 30 3118

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-08-1999

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9302198	A	04-02-1993	FI	913434 A	17-01-1992
WO 9413804	A	23-06-1994	AU	690528 B	30-04-1998
			AU	5654894 A	04-07-1994
			CA	2150262 A	23-06-1994
			EP	0672142 A	20-09-1995
			JP	8504100 T	07-05-1996
			US	5837242 A	17-11-1998
			AT	173740 T	15-12-1998
			AU	680685 B	07-08-1997
			AU	7621494 A	10-04-1995
			CA	2169620 A	30-03-1995
			DE	69414870 D	07-01-1999
			DE	69414870 T	12-05-1999
			EP	0720624 A	10-07-1996
			ES	2126145 T	16-03-1999
			WO	9508577 A	30-03-1995
			JP	9503759 T	15-04-1997
WO 9714719	A	24-04-1997	AU	6873396 A	07-05-1997
			BR	9606706 A	06-04-1999
			CN	1173878 A	18-02-1998
			EP	0799244 A	08-10-1997

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)